September 30, 2021

The SatioPatch™ Platform provides consumer-based diagnosis and eliminates the need for needles administered by a medical professional.

Technology that allows real-time, accurate detection of a wide range of specific targets, and delivers results within minutes.

MORE NEWS

April 14, 2025

Cutting Edge At-Home MedTech and Digital Health Companies, Satio and Nanowear, to Collaborate on Accelerating Non-invasive Biomarkers, Diagnostics and Drug Delivery, Beyond the Remote Monitoring and Digital Assessment Tools Used Today

April 7, 2025

Satio Successfully Completes Development and Testing of Novel At-Home, Remotely Controllable, Intradermal Drug Delivery System, Achieving the First Fully Executed ARPA-H Small Business Contract

April 7, 2025

Small business research team develops low-cost reusable intradermal drug delivery device | ARPA-H

September 26, 2023

Satio Receives Funding From ARPA-H to Develop SatioRx™ a Novel At-home, Remotely Controllable Transdermal Drug Delivery Device

August 18, 2023

Satio partners with BARDA DRIVe to develop a novel patch-based ebolavirus diagnostic

September 9, 2022

Sapphiros Acquires Flexotronix Limited

Sapphiros has today completed the acquisition of Flexotronix Limited.

August 24, 2022

Satio and Institut Pasteur de Dakar Form Strategic Partnership on Research, Development, Manufacture, and Distribution of Next Generation Healthcare Technologies

The partnership aims to enable low-cost access to vaccines and diagnostics to advance public health in Africa and beyond.

August 23, 2022

Satio and INTACT Form Strategic Partnership to Jointly Improve Delivery of Mass Vaccination

Satio and INTACT Solutions have entered into an agreement to establish a collaborative framework in order to partner on research, development, manufacture, and deployment of next generation health technologies with the goal of offering alternative solutions to traditional needles with SatioRx™ intradermal patches for the Member States of the African Union and beyond.